A clinical formulation indicated for Oncology Support. This treatment promotes the inhibition of specific protein kinases to support controlled cellular proliferation.
A targeted cancer therapy designed to manage chronic myeloid leukemia by alleviating tumor growth through the inhibition of specific abnormal proteins.
Mechanism of Action
It inhibits the Bcr-Abl tyrosine kinase, an abnormal protein that signals leukemia cells to multiply. By blocking this signal, it stops the production of cancer cells.
Route of Administration
Oral
Onset Time
Steady state in 8 days
Duration
Requires twice-daily dosing
Contraindications
Long QT syndrome, Severe hypokalemia, Severe hypomagnesemia, Pregnancy
Severe Adverse Events
QT prolongation (heart rhythm danger), Liver toxicity, Severe myelosuppression, Sudden cardiac death
Common Side Effects
Nausea, Rash, Headache, Fatigue
Uncommon Side Effects
Itching, Constipation, Vomiting, Muscle pain, Hair loss
Drug Interactions
Ketoconazole, Rifampin, St. John's wort, Antacids, QT-prolonging drugs
Pregnancy Safety Warnings
Contraindicated; can cause fetal death or birth defects.
Age Restrictions
Approved for adults and children 1 year and older.
Information for Tasigna is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
